Soleus Private Equity Fund III L.P. 13D and 13G filings for Jasper Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 3:32 pm Purchase | 2024-09-30 | 13G | Jasper Therapeutics, Inc. JSPR | Soleus Private Equity Fund III L.P. | 1,343,665 9.000% | 1,343,665 (New Position) | Filing |